Get started
Author

Kristopher Lybarger

Observed names: K. LyBarger, K. Shawn LyBarger, K.S.S. Lybarger, Kristopher LyBarger, kristopher S LyBarger
ORCID: 0009-0005-8255-545X
Observed ORCID: 0009-0005-8255-545X
OpenAlex ID: A5073997219
Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer
2023 · Ignace Vergote, Jose Alejandro Pérez-Fidalgo, et al. · Journal of Clinical Oncology · 77
CA125 as a predictor of endometrial cancer lymphovascular space invasion and lymph node metastasis for risk stratification in the preoperative setting
2022 · K. Shawn LyBarger, Hunter A. Miller, et al. · Scientific Reports · 47
PDF
DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma
2023 · Rebecca Arend, Jhalak Dholakia, et al. · Gynecologic Oncology · 30
Review of Evidence Supporting the Arista™ Absorbable Powder Hemostat
2024 · Kristopher LyBarger · Medical Devices Evidence and Research · 11
PDF
Safety and efficacy of a DKK1 inhibitor (DKN-01) as monotherapy or in combination with paclitaxel in patients with Wnt activated recurrent gynecologic malignancies
2019 · R.C. Arend, C.M. Castro, et al. · Gynecologic Oncology · 7
A clinical marker-based modeling framework to preoperatively predict lymph node and vascular space involvement in endometrial cancer patients
2023 · Hunter A. Miller, Anh Tran, et al. · European Journal of Surgical Oncology · 4
Dkn-01 treated patients with recurrent epithelial endometrial (EEC) or ovarian (EOC) cancers which harbor Wnt activating mutations have longer progression-free survival and improved clinical benefit
2020 · R.C. Arend, C.M. Castro, et al. · Gynecologic Oncology · 3
Patients with recurrent gynecologic cancers and Wnt activating mutations demonstrated greater clinical benefit when treated with DKN-01 therapy
2021 · Rebecca Arend, Cesar Castro, et al. · Gynecologic Oncology · 2
Abstract PO036: Patients with recurrent epithelial endometrial cancers (EEC) and Wnt signaling alterations demonstrated greater clinical benefit when treated with DKN-01 monotherapy
2021 · Rebecca Arend, Cesar Castro, et al. · Clinical Cancer Research · 2
76 Patients (PTS) with recurrent gynecologic cancer whose tumors have activating wnt pathway mutations respond better to DKN-01, a DICKKOPF-1 (DKK1) inhibitor
2019 · R. Arend, C. Castro, et al. · International Journal of Gynecological Cancer · 2
PDF
(ENCORE) Long-term safety and efficacy of selinexor maintenance treatment in patients with TP53 wild-type advanced or recurrent endometrial cancer: Follow-up subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
2025 · Debra Richardson, Vicky Makker, et al. · Gynecologic Oncology
1 - Patients (pts) With Recurrent Gynecologic Cancer Whose Tumors Have Activating Wnt Pathway Mutations Respond Better to Dkn-01, a Dickkopf-1 (dkk1) Inhibitor
2019 · Rebecca Arend, Adam Elnaggar, et al.
Works count: 12
Citation count: 185
H-index: 5
I10-index: 4
Year
Topic
Type